Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 3/20 | 0.31 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700581 | 0.86 | ALDH1A1 (0.43) | ALDH1A1POLBSMN1; SMN2TSHRMEN1 | |
| SCHEMBL15270731 | 0.81 | MLYCD (0.36) | ALDH1A1POLBSMN1; SMN2TSHRMEN1 | |
| SCHEMBL4057292 | 0.79 | CFTR (0.35) | CFTRALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL7938534 | 0.79 | SMN1; SMN2 (0.39) | CFTRALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL15270026 | 0.78 | MLYCD (0.34) | ALDH1A1POLBSMN1; SMN2TSHRMEN1 | |
| SCHEMBL6721810 | 0.77 | ALDH1A1 (0.37) | CFTRALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL3907144 | 0.77 | CFTR (0.38) | CFTRALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL20045680 | 0.76 | CA2 (0.36) | CFTRALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL15923866 | 0.76 | CFTR (0.36) | CFTRALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL15621085 | 0.76 | ALDH1A1 (0.35) | CFTRALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | claimed |
| US-20260028333-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2026-01-29 | — | — | US | claimed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | claimed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | claimed |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-12-14 | — | — | US | claimed |
| WO-2023174836-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2023-09-21 | — | — | WO | claimed |
| EP-4245753-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2023-09-20 | — | — | EP | claimed |
| US-20220388994-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2022-12-08 | — | — | US | claimed |
| EP-4031240-A1 | NEW COMPOUNDS | Vicore Pharma AB (SE) | 2022-07-27 | — | — | EP | claimed |
| CN-114786774-A | Novel compounds | 维科尔药物公司 | 2022-07-22 | — | — | CN | claimed |
| EP-4493546-B1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-20260028333-A1 | NEW COMPOUNDS | VICORE PHARMA AB (SE) | 2026-01-29 | — | — | US | disclosed |
| EP-4493546-A1 | IMIDAZOLE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2025-01-22 | — | — | EP | disclosed |
| US-12152018-B2 | Compounds and compositions for treating conditions associated with STING activity | IFM DUE, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| US-12030856-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2024-07-09 | — | — | US | disclosed |
| WO-2013134298-A1 | RAF INHIBITOR COMPOUNDS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-09-12 | — | — | WO | disclosed |
| WO-2013041652-A1 | MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2013-03-28 | — | — | WO | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-6218498-B1 | USEFUL IN PREPARING MOISTURE CURABLE RTV-1 COMPOSITIONS, AND ARE USEFUL IN DIVERSE PROCESSES WHERE SCAVENGING OF PROTIC MATERIALS, PARTICULARLY WATER, IS DESIRED. | WACKER-CHEMIE GMBH (DE) | 2001-04-17 | — | — | US | disclosed |
| CN-1242016-A | Organosilicon compounds having urea groups, method for producting same and their utilization | WACKER CHEMIE GMBH (DE) | 2000-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028333-A1 | NEW COMPOUNDS | AGTR1, AGTR2, REN | CFTR 10/4885ALDH1A1 2909/4885POLB 3666/4885 |
| US-20220388994-A1 | NEW COMPOUNDS | RXFP3, RXFP4, RXFP1 | CFTR 121/4885ALDH1A1 2970/4885POLB 4323/4885 |
| US-12030856-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | CFTR 121/4885ALDH1A1 1620/4885POLB 4558/4885 |
| US-12152018-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | CFTR 12/4885ALDH1A1 4418/4885POLB 280/4885 |
| US-20230399301-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | CFTR 139/4885ALDH1A1 1874/4885POLB 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.